Catching a Wave: How Much Will CMOs Benefit From Biosimilars?
List Price: US $1,000
Delivery format: Electronic PDF delivery within one business day upon payment.
*This report is included at no extra cost for STRATEGIC ADVANTAGE clients, and is accessible in the Trend Reports section here. Learn more about PharmSource STRATEGIC ADVANTAGE outsourcing intelligence portal.
Regulatory developments in the United States, coupled with impending patent expiry, have paved the way for the introduction of biosimilars of increasing technical complexity. In the European Union, 20 first wave biosimilars, consisting of growth hormones and relatively simple recombinant proteins, have already been approved. Of those first wave biosimilars, 30% have been outsourced to dose manufacturers, and 10% to API manufacturers.
PharmSource’s data-rich Trend Report, Catching a Wave: How Much Will CMOs Benefit From Biosimilars?, concludes that the benefit of biosimilars to the CMO industry is likely to be limited. Biopharma companies or partnerships with significant commercialization and manufacturing capacity are likely to dominate the market for biosimilars and leave the smaller, CMO-dependent companies by the wayside.
The report includes data that is valuable to CMOs and bio/pharmaceutical companies looking strategically at the outsourcing of drug manufacture.
Who should buy this report?
The 12-page report provides important insight that you won’t find in any other source. This report is required reading for:
- CMO executives and strategic decision-makers who seriously follow the global CMO industry, including dose and API manufacturers.
- Bio/Pharma sponsors that buy contract manufacturing services and need to understand contract manufacturing industry drivers.
Published January 2015